Premier Path Wealth Partners’s Arbutus Biopharma ABUS Stock Holding History

Premier Path Wealth Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Sell	30,000 -10,000	-25%	-$43.9K	0.02%	399
2026 Q1	$180K	Hold	40,000	–	–	0.02%	395
2025 Q4	$192K	Hold	40,000	–	–	0.02%	391
2025 Q3	$182K	Hold	40,000	–	–	0.02%	389
2025 Q2	$124K	Hold	40,000	–	–	0.02%	385
2025 Q1	$140K	Hold	40,000	–	–	0.02%	369
2024 Q4	$131K	Hold	40,000	–	–	0.02%	369
2024 Q3	$154K	Buy	40,000 +4,000	+11%	+$15.3K	0.02%	361
2024 Q2	$111K	Buy	36,000 +5,500	+18%	+$16.5K	0.02%	366
2024 Q1	$78.7K	Buy	30,500 +8,300	+37%	+$21.5K	0.01%	341
2023 Q4	$55.5K	Buy	+22,200	New	+$43.5K	0.01%	332

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Premier Path Wealth Partners's ABUS Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its Arbutus Biopharma (ABUS) stake by 25% in Q2 2026, selling an estimated $43.9K and leaving 30,000 shares worth $144K. The position accounts for 0.02% of the portfolio, ranked #399.

Premier Path Wealth Partners first reported a position in ABUS in Q4 2023 and has held it in 11 quarters since. The position peaked at $192K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Premier Path Wealth Partners held 30,000 shares of Arbutus Biopharma worth $144K as of Q2 2026.
Premier Path Wealth Partners sold 10,000 Arbutus Biopharma shares in Q2 2026, an estimated $43.9K.
Arbutus Biopharma made up 0.02% of Premier Path Wealth Partners's portfolio in Q2 2026, its #399 holding.
Premier Path Wealth Partners first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 11 quarters since.
Premier Path Wealth Partners's Arbutus Biopharma position peaked at $192K in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.